7-(4-Bromophenyl)-2-[4-(pyridin-2-yl)piperazin-1-yl]-3H,4H-thieno[3,2-d]pyrimidin-4-one

Catalog No. :
ACKCGP793
CAS No. :
1242964-02-8
Molecular Formula :
C21H18BrN5OS
Molecular Weight :
468.38

IUPAC Name:7-(4-bromophenyl)-2-(4-(pyridin-2-yl)piperazin-1-yl)thieno[3,2-d]pyrimidin-4(3H)-one

7-(4-Bromophenyl)-2-[4-(pyridin-2-yl)piperazin-1-yl]-3H,4H-thieno[3,2-d]pyrimidin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-(4-Bromophenyl)-2-[4-(pyridin-2-yl)piperazin-1-yl]-3H,4H-thieno[3,2-d]pyrimidin-4-one
IUPAC Name7-(4-bromophenyl)-2-(4-(pyridin-2-yl)piperazin-1-yl)thieno[3,2-d]pyrimidin-4(3H)-one
MDL No.MFCD16636203
Molecular FormulaC21H18BrN5OS
Molecular Weight468.38
SMILESO=C1C2=C(C(C3=CC=C(Br)C=C3)=CS2)N=C(N4CCN(C5=NC=CC=C5)CC4)N1
InChI KeyZCCJTBCCAIPNCK-UHFFFAOYSA-N
Synonym7-(4-bromophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)-1H-thieno[3,2-d]pyrimidin-4-one
CAS No.1242964-02-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACKCGP793 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEGJX062 route compound structure diagram
    ACEGJX0625467-74-3 In Stock
  4. Then
  5. ACKCGP793 route product structure diagram
    ACKCGP7931242964-02-8
Inquiry

2. ACKCGP793 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHPYN347 route compound structure diagram
    ACHPYN34768716-49-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKCGP793 route product structure diagram
    ACKCGP7931242964-02-8
Inquiry

Comments (0)